Cargando…
Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes
Objective: Fibroblast growth factor 19 (FGF19) plays an indispensable role in regulating bile acid, glucose, and lipid metabolism, and alterations of its circulating concentration is associated with the development of type 2 diabetes (T2D). Atherosclerosis is directly related to the death-deriving d...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258879/ https://www.ncbi.nlm.nih.gov/pubmed/32528406 http://dx.doi.org/10.3389/fendo.2020.00282 |
_version_ | 1783540117718171648 |
---|---|
author | Hu, Jingyi Liu, Zhiwen Tong, Yue Mei, Zubing Xu, Aimin Zhou, Pengcheng Chen, Xiaoyan Tang, Weili Zhou, Zhiguang Xiao, Yang |
author_facet | Hu, Jingyi Liu, Zhiwen Tong, Yue Mei, Zubing Xu, Aimin Zhou, Pengcheng Chen, Xiaoyan Tang, Weili Zhou, Zhiguang Xiao, Yang |
author_sort | Hu, Jingyi |
collection | PubMed |
description | Objective: Fibroblast growth factor 19 (FGF19) plays an indispensable role in regulating bile acid, glucose, and lipid metabolism, and alterations of its circulating concentration is associated with the development of type 2 diabetes (T2D). Atherosclerosis is directly related to the death-deriving diabetic macroangiopathy in T2D, yet relationships between FGF19 and atherosclerosis in T2D remain unclear. The aim of this study was to investigate the association of circulating FGF19 levels with the development of subclinical atherosclerosis (subAS) in patients with T2D in a 3-year prospective study. Methods: In the present study, 153 newly diagnosed T2D patients without subAS were recruited at baseline, and 137 of them completed a 3-year follow-up. FGF19 levels were measured in fasting serum samples collected at baseline and the third-year visits. Carotid, femoral, and iliac intima-media thickness (IMT) were detected by high-resolution B-mode ultrasound to determine the presence of subAS. Logistic regression analysis was applied to assess the relationship between serum FGF19 and subAS in patients with T2D. Results: At baseline, serum FGF19 levels were positively correlated with carotid IMT and iliac IMT in men (r = 0.239, P = 0.036; r = 0.309, P = 0.006). At the 3-year follow-up, 25 out of 153 patients developed subAS, and FGF19 levels in men were higher in the subAS group than in the non-subAS group [202.7 (177.9–373.6) vs. 133.4 (85.6–171.3) pg/ml, P = 0.028]. Furthermore, in men, higher baseline levels of FGF19 were independently associated with a greater risk of subAS at year 3 in patients with T2D with an odds ratio (OR) of 4.798 per 1 standard deviation (SD) of the FGF19 concentration [OR = 4.798 (95% CI, 1.680–13.706), P = 0.003]. Baseline FGF19 levels yielded an area under the receiver operating characteristic curve of 0.769 to predict the development of subAS at year 3 in men with T2D. Conclusions: Serum FGF19 levels could help in predicting the development of atherosclerosis in men with T2D. |
format | Online Article Text |
id | pubmed-7258879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72588792020-06-10 Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes Hu, Jingyi Liu, Zhiwen Tong, Yue Mei, Zubing Xu, Aimin Zhou, Pengcheng Chen, Xiaoyan Tang, Weili Zhou, Zhiguang Xiao, Yang Front Endocrinol (Lausanne) Endocrinology Objective: Fibroblast growth factor 19 (FGF19) plays an indispensable role in regulating bile acid, glucose, and lipid metabolism, and alterations of its circulating concentration is associated with the development of type 2 diabetes (T2D). Atherosclerosis is directly related to the death-deriving diabetic macroangiopathy in T2D, yet relationships between FGF19 and atherosclerosis in T2D remain unclear. The aim of this study was to investigate the association of circulating FGF19 levels with the development of subclinical atherosclerosis (subAS) in patients with T2D in a 3-year prospective study. Methods: In the present study, 153 newly diagnosed T2D patients without subAS were recruited at baseline, and 137 of them completed a 3-year follow-up. FGF19 levels were measured in fasting serum samples collected at baseline and the third-year visits. Carotid, femoral, and iliac intima-media thickness (IMT) were detected by high-resolution B-mode ultrasound to determine the presence of subAS. Logistic regression analysis was applied to assess the relationship between serum FGF19 and subAS in patients with T2D. Results: At baseline, serum FGF19 levels were positively correlated with carotid IMT and iliac IMT in men (r = 0.239, P = 0.036; r = 0.309, P = 0.006). At the 3-year follow-up, 25 out of 153 patients developed subAS, and FGF19 levels in men were higher in the subAS group than in the non-subAS group [202.7 (177.9–373.6) vs. 133.4 (85.6–171.3) pg/ml, P = 0.028]. Furthermore, in men, higher baseline levels of FGF19 were independently associated with a greater risk of subAS at year 3 in patients with T2D with an odds ratio (OR) of 4.798 per 1 standard deviation (SD) of the FGF19 concentration [OR = 4.798 (95% CI, 1.680–13.706), P = 0.003]. Baseline FGF19 levels yielded an area under the receiver operating characteristic curve of 0.769 to predict the development of subAS at year 3 in men with T2D. Conclusions: Serum FGF19 levels could help in predicting the development of atherosclerosis in men with T2D. Frontiers Media S.A. 2020-05-22 /pmc/articles/PMC7258879/ /pubmed/32528406 http://dx.doi.org/10.3389/fendo.2020.00282 Text en Copyright © 2020 Hu, Liu, Tong, Mei, Xu, Zhou, Chen, Tang, Zhou and Xiao. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Hu, Jingyi Liu, Zhiwen Tong, Yue Mei, Zubing Xu, Aimin Zhou, Pengcheng Chen, Xiaoyan Tang, Weili Zhou, Zhiguang Xiao, Yang Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
title | Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
title_full | Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
title_fullStr | Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
title_full_unstemmed | Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
title_short | Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes |
title_sort | fibroblast growth factor 19 levels predict subclinical atherosclerosis in men with type 2 diabetes |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258879/ https://www.ncbi.nlm.nih.gov/pubmed/32528406 http://dx.doi.org/10.3389/fendo.2020.00282 |
work_keys_str_mv | AT hujingyi fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT liuzhiwen fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT tongyue fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT meizubing fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT xuaimin fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT zhoupengcheng fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT chenxiaoyan fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT tangweili fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT zhouzhiguang fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes AT xiaoyang fibroblastgrowthfactor19levelspredictsubclinicalatherosclerosisinmenwithtype2diabetes |